Pfiz­er reshuf­fles top lead­er­ship to hone com­mer­cial strat­e­gy, leav­ing room for new rare dis­ease chief

Some shuf­fling is tak­ing place at the top ranks of Pfiz­er.

Long­time ex­ec Andy Schmeltz an­nounced on LinkedIn that he’s mov­ing on­to his next tour of du­ty to helm the new­ly es­tab­lished Pfiz­er Com­mer­cial Strat­e­gy & In­no­va­tion (CSI) group, which will be in charge of port­fo­lio strat­e­gy and in­vest­ment de­ci­sions. Tak­ing his place lead­ing the on­col­o­gy unit will be Suneet Var­ma — a fel­low Pfiz­er vet with al­most 22 years at the phar­ma gi­ant — who’s been ap­point­ed as glob­al on­col­o­gy & US pres­i­dent.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER